Announced details
Treatment of achondroplasia (ACH)
The annual height-growth velocity of competing drugs is no more than +1.7 cm. If the Company's drug achieves an annual growth velocity of +2 to +3 cm or more in the Phase 3 trial, it could become a treatment option offering significant benefit.
The Company presented and discussed the results of its Phase 2 clinical trial at the ISDS conference. Capital, personnel and business relationships: not disclosed.
An international organization established in Zurich, Switzerland, in 1999 to promote scientific advances in skeletal dysplasia and skeletal disorders. It holds an annual meeting every 2 years.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
International Skeletal Dysplasia Society (ISDS) conference
| Item | Details |
|---|---|
| Names of Products / Services Covered | umedaptanib pegol (anti-FGF2 aptamer) |
| Counterparty | International Skeletal Dysplasia Society（ISDS） |
| Counterparty overview | An international organization established in Zurich, Switzerland, in 1999 to promote scientific advances in skeletal dysplasia and skeletal disorders. It holds an annual meeting every 2 years. |
| Relationship with the Company | The Company presented and discussed the results of its Phase 2 clinical trial at the ISDS conference. Capital, personnel and business relationships: not disclosed. |
| Applicable area | Treatment of achondroplasia (ACH) |
| Quantitative Effects | The annual height-growth velocity of competing drugs is no more than +1.7 cm. If the Company's drug achieves an annual growth velocity of +2 to +3 cm or more in the Phase 3 trial, it could become a treatment option offering significant benefit. |
| Source | International Skeletal Dysplasia Society (ISDS) conference |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report to investors on the content presented and discussed at the ISDS conference. The company stated that umedaptanib pegol had achieved initial proof of concept and had attracted considerable interest from researchers and patients.